Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | STAMBP | O95630 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216707 | 0.83 | ALDH1A1 (0.50) | MAP4K4 | |
| SCHEMBL30884164 | 0.83 | ALDH1A1 (0.50) | MAP4K4 | |
| SCHEMBL30566473 | 0.79 | NNMT (0.47) | NNMTSMN1; SMN2MKNK1PSMD14STAMBP | |
| SCHEMBL13824870 | 0.79 | NNMT (0.47) | NNMTSMN1; SMN2MKNK1PSMD14STAMBP | |
| SCHEMBL23203545 | 0.79 | NNMT (0.47) | NNMTSMN1; SMN2CHEK2MKNK1FYN | |
| SCHEMBL28509281 | 0.79 | NNMT (0.47) | NNMTSMN1; SMN2CHEK2MKNK1FYN | |
| SCHEMBL17490781 | 0.79 | NOS3 (0.52) | NNMTSMN1; SMN2CHEK2MKNK1FYN | |
| SCHEMBL5904298 | 0.79 | HTT (0.52) | NNMTSMN1; SMN2CHEK2MKNK1FYN | |
| SCHEMBL12716074 | 0.79 | NNMT (0.43) | NNMTSMN1; SMN2MKNK1FYNPSMD14 | |
| SCHEMBL31705858 | 0.76 | KDM4E (0.51) | SMN1; SMN2PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| CN-1255404-C | Process for preparing substituted imidazopyridine compounds | ASTRAZENECA AB (SE) | 2006-05-10 | — | — | CN | disclosed |
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | ELMAN BJORN | 2006-03-23 | — | — | US | disclosed |
| EP-1073657-B1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| CN-1452621-A | Process for preparing substd. imidazopyridine compound | ASTRAZENECA AB (SE) | 2003-10-29 | — | — | CN | disclosed |
| EP-1317455-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020523-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| CN-1307577-A | Imidazo pyridine derivatives which inhibit gastric acid secretion | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-08-08 | — | — | CN | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| US-5863916-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER-EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1999-01-26 | — | — | US | disclosed |
| US-5620978-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | NISCH, CYP1B1, CYP1A2 | NNMT 3678/4885SMN1; SMN2 2455/4885CHEK2 454/4885 |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | NISCH, CYP1A2, CYP1B1 | NNMT 3712/4885SMN1; SMN2 2481/4885CHEK2 404/4885 |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | NNMT 2328/4885SMN1; SMN2 3734/4885CHEK2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.